Form 4: Lalwani Nikhil reports disposition transactions in ANIP

Rhea-AI Filing Summary

Lalwani Nikhil reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 21,986 shares at a weighted average price of $77.01 per share. Following the reported transactions, holdings were 358,574 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Lalwani Nikhil

Role PRESIDENT & CEO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	10,298	$77.36	$797K
Tax Withholding	Common Stock	11,688	$76.70	$896K

Holdings After Transaction: Common Stock — 358,574 shares (Direct)

Footnotes (1)

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 22,849 shares of restricted stock, the grant of which was previously reported on February 18, 2025. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 20,132 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lalwani Nikhil

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		F(1)		11,688	D	$76.7	368,872	D
Common Stock	02/14/2026		F(2)		10,298	D	$77.36	358,574	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 22,849 shares of restricted stock, the grant of which was previously reported on February 18, 2025.

2. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 20,132 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

Remarks:

	/s/ Nikhil Lalwani, by attorney-in-fact Meredith W. Cook	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANIP CEO Nikhil Lalwani report?

Nikhil Lalwani reported two tax-withholding dispositions of ANI Pharmaceuticals common stock. Shares were withheld to cover tax liabilities arising from restricted stock vesting, rather than being sold in open-market transactions.

How many ANI Pharmaceuticals (ANIP) shares were withheld for taxes?

A total of 21,986 shares were withheld for taxes: 11,688 shares on February 12, 2026 at $76.70, and 10,298 shares on February 14, 2026 at $77.36, all in connection with restricted stock vesting.

How many ANIP shares does the CEO own after these transactions?

After the February 14, 2026 transaction, CEO Nikhil Lalwani directly owns 358,574 shares of ANI Pharmaceuticals common stock. This figure reflects his holdings after shares were withheld to satisfy tax obligations on vested restricted stock.

Were the ANIP CEO’s Form 4 transactions open-market sales?

No. Both transactions are coded "F", indicating tax-withholding dispositions. Shares were withheld by the issuer to pay tax liabilities on vested restricted stock, rather than being voluntarily sold in the open market.

What restricted stock vestings are tied to these ANIP share withholdings?

The February 12, 2026 withholding relates to vesting of 22,849 restricted shares granted February 18, 2025. The February 14, 2026 withholding relates to vesting of 20,132 restricted shares granted February 16, 2024, as described in the footnotes.

What is the role of Nikhil Lalwani at ANI Pharmaceuticals (ANIP)?

Nikhil Lalwani serves as President, CEO, and Director of ANI Pharmaceuticals. His Form 4 filing reflects insider ownership changes due to tax withholding on vested restricted stock awards granted in prior years.